Unlocking Success: The PROMISE of a Thriving Public-Private Partnership

The PROMISE (Preparing for RSV Immunisation and Surveillance in Europe) project recently came to a close, delivering tangible results and changing the landscape of RSV prevention and treatment forever. We look back at the journey of this successful public-private partnership in which we had the privilege to participate with our expertise in project management, consortium governance and dissemination.

 

Respiratory Syncytial Virus (RSV) is a common virus responsible for colds in the winter. For most people, RSV causes mild infection, but for very young children, those who are immunocompromised and the elderly, RSV can result in severe disease, causing around 118,000 child deaths every year. Moreover, disease burden is higher in developing countries and, until recently, there were few preventative or therapeutic interventions. This calls for global collaboration to develop novel solutions and lessen RSV disease burden.

The birth of PROMISE

RESCEU (Respiratory Syncytial virus Consortium in EUrope) – the predecessor project to PROMISE which Teamit was also involved in – successfully created a Europe-wide multistakeholder community from academia, industry, patient groups, public health, scientific societies, and regulatory agencies. This project provided a platform for future RSV vaccine and clinical trials. Moreover, RESCEU was associated with tangible outputs relating to better understanding of RSV disease burden and economic impact of RSV infection.

The success of RESCEU led to the development of PROMISE, another Innovative Medicines Initiative (IMI)-funded project, with European partners in academia, industry, and non-profit organisations. Teamit has played a pivotal role in the initiation, development, implementation, and successful completion of this project.

 

Presentations at the PROMISE General Assembly Meeting, March 2022.

Teamit’s role as experts in project management 

Teamit was principally involved in effective coordination and management of this complex project, taking learnings from RESCEU forward into PROMISE and promoting sustainability for these initiatives beyond the project lifetime.

Maica Llavero, Co-head of EU-Funded Projects at Teamit shares some insights on the development of PROMISE and how managing multistakeholder relationships with diverse partners across the public and private sector has been critical to its success:

One of our roles as project managers in PROMISE was to be the glue that connects all the pieces by ensuring that partners communicated and worked together efficiently. We contributed to setting up a solid governance structure and rules of engagement which guaranteed sound and transparent public-private multi-stakeholder collaboration.

Moreover, we have played a key role in communication and dissemination tasks, to effectively convey key project findings to diverse stakeholders.

Berta Gumí Audenis, Head of Training and Education and Project Manager at Teamit explains:

As part of the communication task in the PROMISE project we had the opportunity to support partners in the dissemination of important results to increase their outreach and impact. For example, we helped PROMISE to establish connections with policymakers so that project results could inform their public health strategies to fight RSV.  We also organised capacity building activities addressed to Early Career Researchers (ECR) to upscale their communication and dissemination skills.

PROMISE of public-private partnerships

PROMISE has allowed worldwide partners with diverse expertise to share knowledge and promote discussion to drive forward development of solutions which can reduce the worldwide disease burden of RSV. Building on RESCEU’s results, PROMISE has led to various publications increasing our understanding of RSV disease and our immune response to RSV infection, allowed for completion of vital epidemiology and surveillance studies, as well as increased patient engagement and raised awareness about RSV disease pathology and prevention. Within the project, consortium members also created a Rules of Collaboration document, which outlines the rules of transparent engagement between stakeholders within a public private partnership to maximise the potential of this partnership and project results moving forward.

Reflecting on PROMISE at the final event in March 2024.

Game-changing RSV prevention options

RESCEU and PROMISE endeavours have run in parallel with the approval of novel therapeutics against RSV. In the second half of 2023, a new preventative measure against RSV in the form of a monoclonal antibody developed by project partners Sanofi and AstraZeneca was licensed for use in infants by the European Medical Agency (EMA) and Food and Drugs Authority (FDA) in Europe and the USA, respectively. Moreover, two new RSV vaccines for older people and infants were licensed in 2023 by the EMA representing new preventative measures for groups most at-risk of severe disease. These novel therapeutics illustrate huge progress in the development of effective preventative measures against RSV infection. Collectively, this means that infants born today can receive prophylactic RSV treatment to lessen individual disease burden and improve global health. The collaborative research carried out by RESCEU and PROMISE is now helping health authorities make informed decision on RSV prevention strategies.

PROMISE consortium members at the 2023 General Annual Meeting.

Partnerships to improve quality of life worldwide

Over the last eight years, these consortia have made leaps and bounds to lessen the disease burden of RSV worldwide. RESCEU and PROMISE have illustrated the potential success of public-private partnerships. These diverse multistakeholder relationships have enabled effective collaboration, leading to tangible outputs to improve quality of life worldwide.

At Teamit, we ensure that the partners we work with align with our vision of empowering collaborative research and innovation for a healthier future. We believe that PROMISE is an excellent example of a productive public health project that fulfils our vision, and we are looking forward to supporting outputs related to this project in the future.

Find out more about the other innovative projects we are involved in here.

The PROMISE (Preparing for RSV Immunisation and Surveillance in Europe) project recently came to a close, delivering tangible results and changing the landscape of RSV prevention and treatment forever. We look back at the journey of this successful public-private partnership in which we had the privilege to participate with our expertise in project management, consortium...
Read More
World Environment Day is celebrated every year on June 5th to raise awareness and promote actions to protect our planet. This year’s theme is “Our Land. Our Future. We are Generation Restoration” and focuses on the urgent need to revive ecosystems and “make peace with land”. As an organisation, we are committed to taking steps...
Read More
Head of Partnerships at Teamit, Gianmarco di Mauro to chair a session on Pharmacovigilance and vaccines at the upcoming ISoP Mid-Year symposium in Recinte Modernista de Sant Pau (Barcelona). On 3-4 June 2024, Barcelona will host the International Society of Pharmacovigilance (ISoP) Mid-Year Symposium focused on “The value of real-world data for ensuring patient safety”....
Read More
It’s clear that impactful scientific contributions generated collaboratively are critical to address global health threats. Whilst the challenges ahead are formidable, they also present profound opportunities to effect enduring improvements in the health and well-being of our society. Within the report, you’ll delve into the transformative projects we’ve been involved in and witness the tangible...
Read More
boy receiving bandaid from doctor after vaccine
In the ongoing battle against the COVID-19 pandemic, scientific research continues to pave the way in our understanding of vaccine safety and efficacy. Recently, Teamit Institute (with the great support of study manager Fabio Riefolo) helped make significant strides in this field, participating in two insightful publications on the safety profile of COVID-19 vaccines.  The...
Read More
Teamit is thrilled to announce its participation in launching the EU-funded project WIDEnzymes! Set to revolutionise the enzyme technology landscape across Europe, this 3-year project aims to foster a competitive cross-border ecosystem that not only propels scientific advancements and industrial growth but also champions education and leadership. Importantly, the project will strive to bridge gaps...
Read More
The first International Conference in Drug Repurposing (#iDR24) celebrated in Barcelona on 6-7 March has been in the limelight recently. El País, an influential newspaper in Spain and Latin America, attended the event co-organised by REMEDi4LL and talked to some of the global key opinion leaders in the field of drug repurposing. The extensive article...
Read More
Nearly 250 participants have gathered in Recinte Modernista de Sant Pau 6-7 March to discuss the present and the future of drug repurposing. The 1st International Conference in Drug Repurposing #iDR24 has been organised by the REMEDi4ALL Consortium, Beacon for Rare Diseases and MeRIT. Our stunning headquarters in Recinte Modernista de Sant Pau (Barcelona) have...
Read More
In recent years, the landscape of medical research and innovation has been significantly shaped by a growing focus on rare diseases. At Teamit, our journey into this crucial area has been marked by a series of impactful initiatives and collaborations aimed at addressing the unique challenges faced by individuals affected by rare diseases. The REMEDi4ALLproject,...
Read More